at Investor's Business Daily (Tue, 6:47PM)
Analysts continue to beat the drum for Pfizer PFE witnessed by JPMorgan reiterating an Overweight rating on shares with a $25 price target, following Goldman Sachs adding the firm to its Conviction Buy List yesterday. Shares are down 1.4%, standing as the leader for Dow components on the day.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at MarketWatch.com (Tue, 11:36AM)
at Zacks.com (Tue, 10:19AM)
at Zacks.com (Mon, 5:10PM)
at Zacks.com (Jan 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs